A clinical study on determination of portal venous circulating tumor cells in patients with pancreatic cancer by endoscopic ultrasonography-guided fine needle aspiration
10.3760/cma.j.cn321463-20190714-01241
- VernacularTitle:内镜超声引导下细针穿刺胰腺癌门静脉血测定循环肿瘤细胞的临床研究
- Author:
Chunyan WANG
1
;
Guifang XU
;
Song ZHANG
;
Chunyan PENG
;
Ying LYU
;
Lei WANG
Author Information
1. 南京大学医学院附属鼓楼医院消化科 210008
- From:
Chinese Journal of Digestive Endoscopy
2020;37(3):174-179
- CountryChina
- Language:Chinese
-
Abstract:
Objective:To evaluate the safety and efficacy of circulating tumor cells(CTCs)measurement in patients with pancreatic cancer by endoscopic ultrasonography-guided fine needle aspiration (EUS-FNA).Methods:This prospective, single-center clinical study recruited 5 patients with pancreatic cancer, who underwent EUS-FNA for portal vein blood collection to detect CTCs in portal vein blood and CTCs in peripheral blood as control. CTCs were determined using negative immunomagnetic beads combined with FISH and a folate receptor positive circulating tumor cells detection kit.Results:All 5 patients underwent EUS-FNA portal vein blood collection successfully. One sample developed blood agglutination and failed to perform CTCs test. Four others were tested, and CTCs in portal vein samples and peripheral blood samples were obtained from 3 patients. The mean CTCs in portal vein blood was 10.5±4.0 FU/3.7 mL, and the mean CTCs in peripheral blood was 11.4±4.2 FU/3.7 mL. There was no significant difference between the two groups ( P >0.05). There were no complications such as infection, abdominal bleeding or shock during operation. Conclusion:It is a safe and feasible method to collect and determine the CTCs in portal venous blood from patients with pancreatic cancer under EUS, which helps prediction and treatment of early metastasis of pancreatic cancer.
